Summary Several different drug retreatment protocols were employed to examine the emergence of resistance to MeCCNU in Lewis lung tumours. Previous studies suggested that although the majority of cells in untreated Lewis lung tumours were sensitive to MeCCNU, there was a very small proportion of resistant cells (-0.001%) that limited 'tumour cure' with that drug. If such cells were inherently drug resistant then it should be possible to derive highly resistant tumours by repeated drug treatment.
In the first experiment tumours were treated with a single high dose of MeCCNU (35 or 40mgkg-1) and on regrowth, transplanted into fresh mice and tested for drug sensitivity. Using both excision cell survival and growth delay endpoints, only 25% of tumours were significantly resistant to the test dose, suggesting that many tumours resist the effects of the drug for reasons other than the presence of inherently drug resistant cells. One of the tumours (R4), that regrew after the initial treatment and appeared to be resistant to the test treatment, was retreated with a further 30mg kg-1 MeCCNU and became more resistant. This line, designated R4/1, was cross-resistant to the other nitrosoureas, BCNU and CCNU, but not to cyclophosphamide, melphalan, cis-platinum or ionising radiation.
The effect of treatment dose on the kinetics of MeCCNU resistance development was also studied in a retreatment regimen where the tumours were allowed to regrow and then transplanted into fresh hosts for the next treatment. Resistance developed more quickly at an intermediate dose of 15mgkg-1 than at 7.5mgkg-1 where the selective pressure was lower, or at 30mgkg-1 where there was probably extinction of partially resistant cells.
Resistance to MeCCNU developed even more quickly when tumours were retreated several times in the same host, although in a similar experiment with cyclophosphamide no resistance occurred.
In a recent publication we presented data showing that, although previously untreated Lewis lung tumours appeared to be very sensitive to the cytotoxic nitrosourea MeCCNU using a clonogenic cell survival endpoint, they infact contained a very small subpopulation of cells that were highly resistant to this agent (Stephens et al., 1984) .
In excision cell survival studies, a steep exponential curve (D1O=2mgkg-1) extending down to nearly 5 decades (the limit of sensitivity of the assay) was observed, and it appeared that tumours should be easily cured by MeCCNU doses in the order of 15mgkg-1. This is only 40% of the LD10 (lethal To investigate these possibilities we have used several different drug treatment protocols in an attempt to select intrinsically resistant cells that may be present within Lewis lung tumours. We have also partially characterised one of the resultant tumour lines with respect to its sensitivity to other cytotoxic drugs and radiation. The precise kinetics of emergence of cytotoxic drug resistance during treatment of tumours in vivo has not been widely explored, although we recently reported the kinetics of development of resistance to cyclophosphamide, melphalan and cis-platinum, in the murine MT carcinoma model .
Materials and methods
Mice and tumour Wild-type Lewis lung (LL) carcinoma and the sublines derived in this study, were maintained by i.m. transplantation of 0.5 ml of 1:5 diluted tumour brei, into the gastrocnemius muscles of 20 to 25g C57BI/Cbi mice obtained from the Institute of Cancer Research breeding colony. For experiments, either i.m. tumours in the leg or s.c. tumours in the flank were used when they weighed between 0.15 and 0.25 g.
Drug and radiation treatments The suppliers, preparation and i.p. administration to mice of MeCCNU, CCNU, BCNU, cyclophosphamide (CY), melaphalan and cis-dichlorodiammine platinum (cis-Pt) have all been described in previous publications (Rose et al., 1980; Stephens et al., 1984) .
In experiments on tumour cell radiosensitivity, tumour bearing mice were irradiated to the whole body at a dose rate of approximately 3Gymin-1, using a dedicated 2000Ci tele-cobalt unit . In all cases, tumours were excised for clonogenic assay immediately after irradiation. To determine the hypoxic response of tumour cells, tumour bearing mice were killed 10min before irradiation.
Measurement of tumour cell survival
Tumour cell suspensions for in vitro cell survival assays were prepared by trypsinisation of aseptically excised tumour tissue Tumour cell survival was measured by cloning in soft-agar (Courtenay, 1976) . In a previous publication we noted that LL tumour cell suspensions usually contain significant proportions (-15%) of host cells which can form morphologically distinct colonies in agar. When counting cell suspensions and culture dishes, care was taken to discriminate between tumour and host cells and colonies.
In these experiments the mean tumour cell plating efficiency (PE=number of tumour colonies scored/number of tumour cell plated) of untreated controls was about 0.5, and did not vary significantly between the parent tumour and its sublines.
The effect of drug treatment was expressed as the 'surviving fraction per tumour' (SF per tumour = number of colony forming cells per treated tumour/number of colony forming cells per control tumour). This parameter takes into account drug induced changes in tumour cell yield as part of the overall effect of treatment.
Measurement of tumour regrowth delay The method of evaluating the weight of treated and control i.m. tumours for regrowth delay studies was described in detail by Stephens et al. (1984) . Since at low drug doses tumours often did not shrink below their treatment volume, the response of each individual tumour was evaluated as the time to grow to 4 x its size at the time of treatment (T4 x ). The behaviour of groups of identically treated tumours was expressed as median T4 x with 25th and 75th percentiles. Growth delay was calculated as: (median T4 x of treated tumours) -(median T4 x of untreated controls). 
Lung cloning

EMERGENCE OF NITROSOUREA RESISTANT TUMOUR LINES
In the first experiment, four i.m. tumours which regrew following treatment with 40mg kg-1 MeCCNU, were each transplanted into 20 mice. When these tumours had grown to a size of 0.2 g, they were then again treated with MeCCNU at a range of doses, and excision cell survival and growth delay were both measured. Figures 1 and 2 show that three of these tumours (designated RI, R2, and R3), which had resisted high-dose MeCCNU, were at least as sensitive as wild-type tumours (wild-type LL response curves are shown dashed in the figures), although the fourth tumour (R4), was significantly more resistant. R4 had an increased D10 of 4.9mg kg-1 (compared to 2mg kg-1 for wild-type LL), and the resistant tail on the growth delay curve was more apparent. There was also a suggestion that R3 may be more sensitive to MeCCNU than wild-type LL, as indicated by the growth delay endpoint.
Two tumours derived from R4, were treated for a second time with 30mg kg-1 MeCCNU, and on regrowth they were re-passaged into fresh mice to yield sub-lines R4/1 and R4/2. When these lines were tested again for MeCCNU sensitivity, there was a further increase in the degree of resistance, seen as reduced survival curve slope (R4/1 terminal DIO=8.6mgkg-1) and the appearance of a shoulder (n=3.5, Figure 1 ) and a reduction in growth delay (Figure 2 ). Line R4/1 has retained its resistant characteristics for more than 50 passages without further treatment. In order to confirm these results, a second experiment utilizing only growth delay was performed. The results are shown in Table I . Again, most of the tumours (5/7) which regrew after 30mgkg-1 MeCCNU were as sensitive, or more sensitive than wild-type LL, when transplanted and tested in fresh mice. In addition, four tumours transplanted from RIO (which were at least as sensitive to MeCCNU as wild-type LL), were retreated with 30mg kg-1 MeCCNU, allowed to regrow, transplanted and re-tested (RIO/I, RIO/2, RlO/3, RIO/4). They were found to be mostly sensitive (3/4), although one was highly resistant.
From these results it seems that -75% of tumours regrowing after high-dose MeCCNU treatment are as drug sensitive as wild-type LL, and that MeCCNU resistance in previously untreated LL tumours cannot be simply explained by the presence of a minority of inherently resistant cells, unless these cells reverted to a sensitive phenotype after the initial selection. However, some tumours obviously do resist the effects of MeCCNU due to the presence of inherently resistant cells.
MeCCNU resistance in clonal LL lines
An experiment was performed to investigate whether clonal LL lines had the same sensitivity to In the initial experiment five mice bearing bilateral 0.2 g s.c. tumours were treated with 15mg kg-1 MeCCNU and growth delay was measured. The first tumour to regrow to 4 x treatment size was transplanted into ten fresh mice, and on reaching 0.2 g was again treated with 15mgkg-t MeCCNU and growth delay measured. This procedure was repeated nine times, whereupon, the tumour had become highly drug resistant, as indicated by negligible regrowth delay (Figure 3, closed symbols) . In fact, it appeared that the resistance was already near its maximum after only five MeCCNU retreatments, and at this point, a second tumour line was established which was passaged without further treatment in order to observe the stability of resistance. This line was tested for MeCCNU sensitivity every few passages and retained the resistance that it had initially developed in the five treated passages (Figure 3 , open symbols). In a second experiment three different doses of MeCCNU were used to retreat tumours (7.5, 15 and 30mg kg-1), in order to study the rate of resistance induction as a function of drug dose. Figure 4A shows the changes in growth delay with treatment at the three dose levels. Although it appeared that resistance developed faster at lower doses than at higher doses (more treatments were EMERGENCE OF NITROSOUREA RESISTANT TUMOUR LINES 241 unrealistic compared to the clinical situation where a tumour is repeatedly treated within the same host. The outcome of the above experiments might be influenced by the need to transplant tumour between treatments. The most likely problem is that at the start of a retreatment protocol we may, by transplanting only a small amount of tumour tissue, fail to include resistant cells, and thereby underestimate the true rate of resistance development.
An experiment was therefore designed to study the development of MeCCNU resistance within a single mouse. Figure 5A shows the median 0 Passage number Figure 4 Effect of dose on the rate of development of MeCCNU resistance in a multiple drug retreatment/ transplantation regimen. The procedure to develop drug resistance is the same as that described in the legend for Figure 3 . (a) This shows the changes in growth delay incurred by repeated treatments with MeCCNU at 30(g), 15(0) or 7.5mgkg-1 (A). (b) From the data in (a) it is difficult to determine the rates of resistance development at the different dose levels, because the initial growth delay varies widely. Thus, tumours that had been retreated repeatedly with 7 5(A) or 30mgkg-1(El) MeCCNU were tested in thb next passage with 15mg kg1, and this data was compared with 15mg kg1 (0) retreatments. Error bars as in Figure 2. required to reduce growth delay to a low value), this may be misleading because the extent of change in growth delay varies with dose. To overcome this problem, tumours lines that had been retreated with 7.5 or 30mg kg-1 were each tested in the next passage with 15mg kg-1, so that they could be directly compared with the 15mg kg-1 data. Figure  4B then shows that resistance induction was slightly slower at both 7.5 and 30 mg kg1, than at 15mgkg-1. Figure SB) had not developed any drug resistance as indicated by consistent levels of growth delay (11.35, 8.6, 11, and 9.9 
days).
Cross-resistance to other drugs and radiation Lastly, experiments were perfoimed to characterise one of the MeCCNU resistant lines (R4/1) for cross-resistance to some other related nitrosoureas, and commonly used cytotoxic agents. Table II summarises the results of excision cell survival experiments to compare the sensitivity of R4/1, and wild-type LL. Drug sensitivity was expressed in terms of survival curve slope, with extent of cross-resistance indicated by the ratio: (R4/1 curve slope)/(LL curve slope). As might be expected, tumour line R4/1 was cross-resistant (as indicated by a ratio that was > 1) to the other nitrosoureas CCNU and BCNU, but not (ratio= 1) to the alkylating agents CY and melphalan, or the DNA cross-linking cis-Pt.
There was also no difference in the response of R4/1 and LL to ionising radiation as judged by excision cell survival immediately following acute treatment under either air-breathing or hypoxic conditions (data not shown). In each case, the Do of hypoxic tumour cells was -3.2 Gy, with an extrapolation number (n) of 8, and the hypoxic fraction of tumours in air-breathing mice was 10%.
Discussion
In this paper we have demonstrated that some tumours that regrow after high, theoretically curative, doses of MeCCNU contain cells that are inherently resistant to the drug. The resistant cells were revealed by several different retreatment regimes designed to selectively kill MeCCNU sensitive tumour cells, and to lead to the selection of highly resistant tumour cell populations that retained resistance during passage without further treatment. A similar phenomenon has been described previously by Griswold (1974) , who developed a line of B16 melanoma that was highly resistant to MeCCNU after only three retreatments, but he did not explore the kinetics of resistance development as described here.
However, in our studies, only a minority (-25%) of tumours that regrew following treatment with single high MeCCNU doses (30-40mgkg-1) that should have killed the drug sensitive cells, were subsequently found to retain resistance to a second test treatment. These resistant tumours presumably contained an enriched proportion of inherently resistant cells that could be selected further by additional treatment, although some other mechanism must be responsible for resistance in the majority of singly treated tumours that should have been cured if they consisted only of drug sensitive cells. Although inherently sensitive cells might be protected in kinetic, pharmacological or environmental sanctuaries, the apparent rarity of such sanctuaries makes this suggestion, to us, unlikely. Only 1 in 105 tumour cells are resistant according to the survival curve published in our previous paper (Stephens et al., 1984) and this is supported by growth delay data. The growth delays for wildtype and sensitive tumour lines treated with 25mg kg-I MeCCNU were 15 to 20 days (Table I) and assuming a 1 day doubling time for surviving cells, this translates into 5 to 6 decades of cell killing.
The experiments presented here were specifically designed to explore the kinetics of development of cytotoxic drug resistance, following the interest shown in the work of Goldie & Coldman (1979) on the possible emergence of drug resistant cells in tumours as the result of spontaneous mutation, and the subsequent selection of resistant cells that will occur with continued treatment (Skipper et al., 1978) . Some of the limitations of these ideas have been discussed in a previous paper (McMillan et al., 1985) .
The development of resistance to nitrosoureas is especially interesting because one of the principal mechanisms has been determined at the molecular level. This is the increased capacity of some cells to repair lesions in their DNA, by the specific removal of alkyl groups from the 06 position of guanine residues of DNA, due to the presence of increased levels of the receptor protein 06-methyl guanine-DNA methyltransferase Yarosh et al., 1983) . The primary site of interaction between monofunctional nitrosoureas and DNA is apparently the 06 position of guanine, and bifunctional nitrosoureas appear first to react with this site, and later to react again either with DNA or protein to form cross-links. Removal of the monoadduct from the DNA prevents the apparently lethal cross-linking step (Erickson et al., 1980; Meyn et al., 1982; Robins et al., 1983; Brent, 1984) . We have evidence that MeCCNU resistance in our line R4/1 involves increased levels of 06-methylguanine-DNA methyltransferase (in preparation).
The kinetics of development of MeCCNU resistance during retreatment regimes involving transplantation into fresh hosts between drug doses is fairly well defined by our data, although there are several complicating factors in the interpretation of Figures 3 and 4 . At an intermediate drug dose of 15mg kg-1, tumours appeared to be equally sensitive to the first two drug doses using a median growth delay endpoint. Since this MeCCNU dose apparently killed -6 decades of sensitive tumour cells and the tumour only started with around 108 clonogenic cells, then some enrichment of preexisting resistant cells might have been expected due to the selective pressure of the first treatment, making the second dose less effective. However, the resistant cells are not totally resistant, and the initial population could have been reduced by about 1 decade, perhaps enough to destroy all resistant cells in some tumours (we call this phenomenon 'extinction'). Wide variations in the numbers of resistant cells within individual tumours is predicted by Goldie & Coldman (1979) , as a consequence of spontaneous mutation to the resistant phenotype. Alternatively resistance may develop more slowly if resistant cells were lost during transplantation between treatments due to inadequate sampling. This is possible because in our transplantation protocol we only transfer 106 viable cells. Also, the development of resistance could differ if the growth rate of sensitive and resistant cells was not the same. Small differences in cell doubling times during tumour regrowth and after transplantation could change the ratio of sensitive to resistant cells present at the next treatment. Although there was no suggestion of this from the shapes of tumour growth curves during retreatment protocols that produced highly resistant tumours, resistant line R4/1 does grow marginally faster than wild-type LL.
At the higher MeCCNU dose of 30mg kg1 a greater proportion of sensitive cells should be killed with each dose, but also more resistant cells should be killed, with a greater probability of their extinction. Thus, the development of resistance could be delayed ( Figure 4B ). The lower dose (7.5mg kg-1) should kill fewer tumour cells and resistant tumours would be expected to take longer to emerge under the lower selective pressure ( Figure  4B ). There is reason to believe that the above assumption (based on Goldie & Coldman, 1979) that MeCCNU resistant cells can emerge as a result of spontaneous mutation during the course of tumour growth is more likely than the alternative suggestion, that a preexisting population of resistant cells is transplanted from passage to passage. Clonal LL lines were found to be no different in sensitivity to MeCCNU than the highly passaged wild-type tumour and some must have contained a small proportion of resistant cells that had developed during growth from a single cell. Conclusive evidence for this has been obtained by McMillan (1985) , who derived four clonal LL lines, and each became highly, and permanently resistant, following four retreatments with 15mg kgMeCCNU.
Another mechanism that could conceivably be involved in the acquisition of permanent drug resistance, is the induction of mutations by the first treatment with a drug, that confers resistance to subsequent treatments with the same drug. We are not aware that this has ever been demonstrated with a cytotoxic drug, although we have enhanced the induction of resistance to CY in MT carcinoma by pretreatment of the tumour cells with the classical mutagen ethyl methanesulphonate . MeCCNU and other nitrosoureas are significantly mutagenic in the Ames Salmonella typhimurium assay (Franza et al., 1980) , and in chinese hamster cells, at the HGPRT locus as 6-thioguanine resistance (Bradley et al., 1980) . However, the likelihood that a specific mutation conferring resistance to MeCCNU should occur in the small population of survivors from high-dose MeCCNU seems slim. Nevertheless, this could explain the delayed development of resistance to MeCCNU until at least two drug treatments had been given (Figures 3 and 4) .
Although MeCCNU resistance developed quite quickly in the retreatment experiments involving transplantation, it developed even more quickly when treatments were administered to a single host without transplantation ( Figure 5A ). By the third treatment tumours were almost totally resistant as indicated by a lack of growth delay. However, there could be several possible explanations of this resistance. In addition to the possible selection of inherently resistant tumour cells without the complications of resistant cell loss at transplantation, which would tend to reduce the rate of resistance development, the pharmacokinetics of the drug may have changed. Induction of catabolising enzymes in the mouse liver or elsewhere may reduce the antitumour activity of the drug. However, extinction of resistant cells is still possible in this style of experiment. In contrast, the activity of CY was unchanged as indicated by a constant substantial growth delay during four treatments ( Figure 5B) .
In a previous paper we attempted, unsuccessfully, to model mathematically the emergence of resistance to melphalan in the MT carcinoma during a retreatment protocol . Efforts to model our data also failed and it seems to us that the ideas of Goldie & Coldman (1979) , and Skipper et al. (1978) , may be too simplistic to adequately fit real data.
The MeCCNU resistant subline, R4/1, was characterised for cross-resistance to some other agents. It was found to be cross-resistant with other bifunctional nitrosoureas (CCNU and BCNU), but not with the alkylating agents CY and melphalan, the DNA cross-linking agent cis-Pt, or ionising radiation. Although cross-resistance between nitrosoureas, possibly due to enhanced 06-methylguanine-DNA methyl transferase levels, is commonly found, cross-resistance to CY (Skipper et al., 1972) and melphalan (Burman & Steel, 1984) have been reported in some tumour cell lines although these agents do not react primarily at this site in DNA.
We are currently attempting to establish more clearly the mechanism of resistance to MeCCNU in the majority of tumours, that does not appear to involve permanent acquisition of a resistant phenotype. Having shown that LL subline R4/1 has increased ability to repair 06-alkylguanine lesions of DNA (in preparation), we are considering the testable hypothesis that transient increases in the intracellular level of 06-methylguanine-DNA methyltransferase may protect inherently sensitive cells from killing by MeCCNU. We are not aware of any other in vivo studies in which apparently transient drug resistance has been reported, and this may represent an important new type of drug resistance.
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